🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

Recruitingn/aAges 18 Years - anyAllNantes University Hospital
NCT07423429 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections. This multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (≥18 years) with exudative (neovascular) age-related macular degeneration * Treated with intravitreal anti-VEGF therapy for more than 1 year * Switched to aflibercept 8 mg before July 31, 2025 * Injection interval strictly less than 12 weeks prior to switch Exclusion Criteria: * High myopia (axial length \> 26 mm or spherical equivalent \< -6 diopters) * Angioid streaks * Moderate or severe diabetic retinopathy * History of diabetic macular edema * History of uveitis * History of retinal vein occlusion (branch or central) * History of pseudovitelliform macular dystrophy * Patient under legal guardianship or curatorship * Pregnant or breastfeeding women
💊

What it tests

  • aflibercept 8 mg
📍

Where

1 site
CHU Nantes - Ophthalmology Department
Nantes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy